T. Kenneth Mills's Insider Trades & SAST Disclosures
T. Kenneth Mills's most recent trade in Regenxbio Inc was a trade of 20,602 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on May 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern T. Kenneth Mills.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2025 | 20,602 | 0 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Sale of securities on an exchange or to another person at price $ 7.91 per share. | 12 May 2025 | 20,602 | 475,103 (1%) | 0% | 7.9 | 163,046 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 12 May 2025 | 20,602 | 495,705 (1%) | 0% | 3.8 | 77,464 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 30,752 | 20,602 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 27 Mar 2025 | 30,752 | 475,103 (1%) | 0% | 3.8 | 115,628 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | 08 Aug 2024 | 36,316 | 0 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 08 Aug 2024 | 36,316 | 444,351 (1%) | 0% | 0.9 | 30,869 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 15,369 | 51,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 15,369 | 408,035 (1%) | 0% | 14.0 | 214,501 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 15,369 | 423,404 (1%) | 0% | 3.8 | 57,787 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 12,221 | 420,256 (1%) | 0% | 3.8 | 45,951 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 12,221 | 66,723 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 12,221 | 408,035 (1%) | 0% | 13.8 | 168,433 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 2,210 | 78,944 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 2,210 | 408,035 (1%) | 0% | 13.8 | 30,440 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 2,210 | 410,245 (1%) | 0% | 3.8 | 8,310 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 200 | 408,035 (1%) | 0% | 13.8 | 2,752 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 200 | 81,154 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 200 | 408,235 (1%) | 0% | 3.8 | 752 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 May 2024 | 15,000 | 81,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 May 2024 | 15,000 | 408,035 (1%) | 0% | 15.8 | 237,222 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 May 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 15 Apr 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 15 Apr 2024 | 15,000 | 96,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 15 Apr 2024 | 15,000 | 408,035 (1%) | 0% | 18.2 | 272,871 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 Mar 2024 | 15,000 | 111,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 Mar 2024 | 15,000 | 408,035 (1%) | 0% | 21.9 | 327,942 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 Mar 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 14 Feb 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 14 Feb 2024 | 15,000 | 126,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 14 Feb 2024 | 10,348 | 408,035 (1%) | 0% | 16.9 | 174,723 | Common Stock | |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | 14 Feb 2024 | 4,652 | 418,383 (1%) | 0% | 16.5 | 76,626 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 16 Jan 2024 | 45,000 | 141,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | 16 Jan 2024 | 45,000 | 408,035 (1%) | 0% | 15.2 | 682,992 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 16 Jan 2024 | 45,000 | 453,035 (1%) | 0% | 3.8 | 169,200 | Common Stock | |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | 02 Jan 2024 | 305,250 | 305,250 | - | - | Stock Options (Right to buy) | ||
| Regenxbio Inc | Mills T. Kenneth | Director, President and CEO | 02 Jan 2024 | 64,103 | 408,035 (1%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 02 Jan 2024 | 11,357 | 343,932 (0%) | 0% | 17.9 | 203,858 | Common Stock | |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | 19 Dec 2023 | 45,000 | 355,289 (0%) | 0% | 19.7 | 885,825 | Common Stock | |
| Regenxbio Inc | T. Mills Kenneth | Director, President and CEO | 19 Dec 2023 | 43,500 | 186,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | 19 Dec 2023 | 43,500 | 398,789 (1%) | 0% | 3.8 | 163,560 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 19 Dec 2023 | 1,500 | 36,316 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | 19 Dec 2023 | 1,500 | 400,289 (1%) | 0% | 0.9 | 1,275 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 03 Jan 2023 | 264,932 | 264,932 | - | - | Stock Options (Right to buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 03 Jan 2023 | 54,753 | 355,289 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 03 Jan 2023 | 9,308 | 300,536 (0%) | 0% | 22.7 | 211,105 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 01 Jan 2022 | 170,188 | 170,188 | - | - | Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 01 Jan 2022 | 35,796 | 309,844 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 01 Jan 2022 | 3,636 | 274,048 (0%) | 0% | 32.7 | 118,897 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 02 Dec 2021 | 3,300 | 277,684 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 08 Nov 2021 | 1,500 | 280,984 (0%) | 0% | 40 | 60,000 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 08 Nov 2021 | 1,500 | 229,854 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 08 Nov 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 27 Sep 2021 | 1,500 | 280,984 (0%) | 0% | 42.2 | 63,285 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 27 Sep 2021 | 1,500 | 231,354 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 27 Sep 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 35,000 | 280,984 (0%) | 0% | 45.1 | 1,578,850 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 33,146 | 232,854 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 33,146 | 314,130 (0%) | 0% | 3.8 | 124,629 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 3,000 | 266,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 3,000 | 280,984 (0%) | 0% | 40.0 | 120,060 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 3,000 | 283,984 (0%) | 0% | 3.8 | 11,280 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 1,854 | 37,816 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 1,854 | 315,984 (0%) | 0% | 0.9 | 1,576 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 4,500 | 280,984 (0%) | 0% | 40.0 | 180,090 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 4,500 | 285,484 (0%) | 0% | 3.8 | 16,920 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 4,500 | 270,500 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 1,500 | 269,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 1,500 | 280,984 (0%) | 0% | 40.3 | 60,375 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Feb 2021 | 1,500 | 280,984 (0%) | 0% | 40.8 | 61,155 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Feb 2021 | 1,500 | 39,670 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Feb 2021 | 1,500 | 282,484 (0%) | 0% | 0.9 | 1,275 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Jan 2021 | 6,500 | 287,484 (0%) | 0% | 0.9 | 5,525 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Jan 2021 | 6,500 | 41,170 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Jan 2021 | 5,211 | 280,984 (0%) | 0% | 45.0 | 234,443 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Jan 2021 | 974 | 286,195 (0%) | 0% | 44.1 | 42,905 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Jan 2021 | 315 | 287,169 (0%) | 0% | 42.6 | 13,432 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 07 Jan 2021 | 1,500 | 283,484 (0%) | 0% | 0.9 | 1,275 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 07 Jan 2021 | 1,500 | 47,670 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 07 Jan 2021 | 1,500 | 281,984 (0%) | 0% | 50.0 | 75,015 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 04 Jan 2021 | 185,167 | 185,167 | - | - | Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 04 Jan 2021 | 40,984 | 281,984 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 28 Dec 2020 | 6,500 | 49,170 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 28 Dec 2020 | 6,500 | 247,500 (0%) | 0% | 0.9 | 5,525 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 28 Dec 2020 | 4,647 | 242,853 (0%) | 0% | 48.5 | 225,240 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 28 Dec 2020 | 1,853 | 241,000 (0%) | 0% | 49.2 | 91,093 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 23 Dec 2020 | 4,500 | 241,000 (0%) | 0% | 50 | 225,000 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 23 Dec 2020 | 4,500 | 55,670 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 23 Dec 2020 | 4,500 | 245,500 (0%) | 0% | 0.9 | 3,825 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 16 Dec 2020 | 15,000 | 241,000 (0%) | 0% | 45 | 675,000 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 16 Dec 2020 | 15,000 | 60,170 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 16 Dec 2020 | 15,000 | 256,000 (0%) | 0% | 0.9 | 12,750 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 10 Dec 2020 | 4,500 | 241,000 (0%) | 0% | 40 | 180,000 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 10 Dec 2020 | 4,500 | 75,170 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 10 Dec 2020 | 4,500 | 245,500 (0%) | 0% | 0.9 | 3,825 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges